HC Wainwright Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $15.00

Intellia Therapeutics (NASDAQ:NTLA) had its price objective lowered by stock analysts at HC Wainwright from $18.00 to $15.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 57.56% from the stock’s previous close.

Several other research analysts have also recently weighed in on NTLA. Wall Street Zen cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Barclays reduced their price objective on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday. Robert W. Baird set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, October 30th. JPMorgan Chase & Co. reissued an “underweight” rating and set a $5.00 target price (down from $12.00) on shares of Intellia Therapeutics in a research note on Friday. Finally, Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. Twelve equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.26.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $9.52 on Monday. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The firm has a market capitalization of $1.02 billion, a PE ratio of -2.23 and a beta of 2.45. The company’s 50 day simple moving average is $17.19 and its 200 day simple moving average is $12.53.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.12 million. During the same period last year, the company posted ($1.34) EPS. The firm’s quarterly revenue was up 51.6% on a year-over-year basis. Sell-side analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. The trade was a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William J. Chase acquired 100,000 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This represents a 288.24% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Intellia Therapeutics by 86.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 38,816 shares of the company’s stock worth $670,000 after purchasing an additional 18,012 shares during the period. Jupiter Asset Management Ltd. acquired a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $23,519,000. Readystate Asset Management LP purchased a new stake in Intellia Therapeutics in the 3rd quarter worth approximately $1,283,000. Axxcess Wealth Management LLC boosted its stake in shares of Intellia Therapeutics by 11.5% during the 3rd quarter. Axxcess Wealth Management LLC now owns 17,816 shares of the company’s stock valued at $308,000 after buying an additional 1,839 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Intellia Therapeutics by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock valued at $190,744,000 after buying an additional 192,651 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.